Lisocabtagene maraleucel: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
Lisocabtagene maraleucel: clinical details
Prescribing considerations
- Restrict initiation and administration to qualified centres with trained haematology and CAR T-cell toxicity services, emergency equipment and immediate access to appropriate cytokine release syndrome treatment.
- Confirm product availability and reassess clinical status before preparative treatment and infusion.
- Delay infusion for unresolved serious adverse events, uncontrolled infection or inflammatory disease, or active graft-versus-host disease.
- Verify patient identity against the shipper, cartons, labels and release-for-infusion certificates; the product is strictly autologous.
- Screen for HIV, active hepatitis B and hepatitis C before cell collection. Consider antiviral suppression for patients with previous hepatitis B infection.
- Explain alert-card use, proximity requirements, driving restrictions, donation prohibition and long-term follow-up.
Contraindications and cautions
- Hypersensitivity to an excipient.
- Any contraindication to the required lymphodepleting chemotherapy must also be considered.
- Do not administer to anyone other than the person from whom the cells were collected.
- Avoid administration during clinically significant active infection or inflammatory disease; active graft-versus-host disease is a reason to delay treatment.
Monitoring
- Assess for cytokine release syndrome and neurological toxicity, including delayed presentations.
- Monitor blood counts before and after treatment for prolonged cytopenias.
- Monitor for bacterial, viral and fungal infection and viral reactivation.
- Monitor immunoglobulins and manage B-cell aplasia or hypogammaglobulinaemia where clinically indicated.
- Assess patients at risk of tumour lysis syndrome and monitor relevant clinical and laboratory findings.
- Provide lifelong surveillance for secondary malignancies, including T-cell malignancy; maintain mandated product traceability.
Clinical pharmacology
A defined-composition autologous cellular immunotherapy containing separately manufactured CD8-positive and CD4-positive T cells expressing an anti-CD19 CAR with CD3-zeta activation and 4-1BB co-stimulatory signalling. CD19 binding drives T-cell activation, proliferation, cytokine release and cytotoxic killing; cells may persist in peripheral blood long after infusion.
Formulation and product differences
- Supplied as separate cryopreserved CD8-positive and CD4-positive cell dispersions, each potentially contained in multiple patient-specific vials.
- The required vial count and volume vary by batch and are specified on separate release-for-infusion certificates.
- Contains human albumin and dimethyl sulfoxide; the latter may contribute to serious hypersensitivity reactions.
- The thawed product must not be refrozen or mixed with other medicinal products.
Lisocabtagene maraleucel interactions
Formal human interaction studies have not been performed. Important treatment-related considerations include:
Live viral vaccines
Avoid around treatment and until immune recovery because safety has not been established; agree vaccination plans with the specialist team.
Anti-EGFR monoclonal antibodies
Later use might affect the long-term persistence of the modified T cells, although clinical information is limited.
Systemic corticosteroids
Routine preventive use around infusion is avoided because it may interfere with CAR T-cell activity; corticosteroids may still be required under specialist direction to manage toxicity.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.